

Figure S1. **Actin and tubulin rearrangements on neutrophil activation and NET formation.** Neutrophils ( $2 \times 10^6$  cells/ml) were primed with 25 ng/ml GM-CSF for 20 min and subsequently stimulated with  $10^{-8}$  M C5a for 15 min. **(A)** Confocal microscopy. Snapshots of live cell analysis by using *Lifact-EGFP* mouse neutrophils labeled with SiR-tubulin and Hoechst 33342 (corresponding to Video 1). **(B)** Flow cytometry. Analysis of F-actin polymerization on activation by using phalloidin (green).  $n = 5$ . **(C)** Confocal microscopy. DNA release was analyzed after short-term stimulation (total 35 min) of mouse neutrophils with the indicated triggers.  $n = 3$ . **(D)** Confocal microscopy. F-actin distribution and morphological changes were analyzed after short-term stimulation (total 35 min) of mouse neutrophils with the indicated triggers.  $n = 3$ . Bars, 10  $\mu$ m.








Figure S2. **Degranulation in the activated human neutrophils: surrogate markers and the release of azurophilic (N-acetyl-β-glucosaminidase) and tertiary (MMP-9) granules.** Human neutrophils ( $4 \times 10^6$  cells/ml) were primed with 25 ng/ml GM-CSF for 20 min followed by 15 min stimulation with  $10^{-8}$  M C5a. Pretreatment of neutrophils with 5 μM DPI, 10 μM Lat B, 1 μM taxol, or 5 μM nocodazole was done 30 min before activation. **(A)** Flow cytometry. Optimal antibody titer for cell surface expression of CD63, CD66b, and CD35. **(B and D)** β-glucosaminidase release. **(C and E)** MMP-9 release. Data are means ± SEM. \*\*,  $P < 0.0078$ ; \*\*\*,  $P < 0.001$ .




Figure S3. **Immunophenotypic and morphological characterization of mature Hoxb8 mouse neutrophils.** (A) Flow cytometry. Cell surface expression of Ly6G in WT, *Nox2<sup>-/-</sup>*, *Grx1<sup>-/-</sup>*, and *Was<sup>-/-</sup>* Hoxb8 mouse neutrophils after differentiation. (B) Cytology. Nuclear morphology of Hoxb8 mouse neutrophils was analyzed by light microscopy. Representative data are shown.




Figure S4. **Degranulation of activated *Was*<sup>-/-</sup>, *Nox2*<sup>-/-</sup>, and *Grx1*<sup>-/-</sup> neutrophils was compromised compared with that of WT neutrophils.** Mouse neutrophils ( $4 \times 10^6$  cells/ml) were primed with 25 ng/ml GM-CSF for 20 min followed by 15 min stimulation with  $10^{-8}$  M C5a. MMP-9 release was measured in the supernatants of activated cells by ELISA. The amount of  $\beta$ -glucosaminidase activity released in supernatants of neutrophils was expressed as a percentage of the total  $\beta$ -glucosaminidase. **(A and B)** Comparison between WT and *Was*<sup>-/-</sup> neutrophils. **(C and D)** Comparison between WT and *Nox2*<sup>-/-</sup> neutrophils. **(E and F)** Comparison between WT and *Grx1*<sup>-/-</sup> neutrophils. Data are means  $\pm$  SEM. \*\*\*,  $P < 0.001$ ; \*\*,  $P < 0.01$ ; \*,  $P < 0.05$ .  $n = 4$ .




Figure S5. **NADPH oxidase but not actin glutathionylation or MT formation regulates ROS production in mouse and human neutrophils.** Flow cytometry. Total ROS activity of human and mouse neutrophils after short-term stimulation (total 35 min) with the indicated triggers was assessed by using DHR123 fluorescence. **(A)** Comparison between control and CGD human neutrophils.  $n = 3$ . **(B)** Comparison between WT and *Nox2*<sup>-/-</sup> mouse neutrophils.  $n = 4$ . **(C)** Comparison between human neutrophils in the presence and absence of the indicated inhibitors.  $n = 5$ . **(D)** Comparison between differentiated Hoxb8 mouse neutrophils and neutrophils transfected with EGFP-β-actin-Cys<sup>374</sup> (WT) or point-mutated constructs having Cys<sup>374</sup> changed to Ala<sup>374</sup> or Glu<sup>374</sup>.  $n = 5$ . **(E)** Comparison between human neutrophils in the presence and absence of the indicated inhibitors.  $n = 5$ . Data are means ± SEM. \*\*\*,  $P < 0.001$ ; \*,  $P < 0.05$ .





Figure S6. Sodium-arsenite (50 μM), CdCl<sub>2</sub> (2 μM), and H<sub>2</sub>O<sub>2</sub> (50 μM) do not induce death in human and mouse neutrophils. (A–C) Flow cytometry. Viability of mouse and human neutrophils was analyzed in a time-dependent manner by using an ethidium bromide exclusion assay with flow cytometry. (A and C) Human neutrophils. (B) WT and *Nox2*<sup>-/-</sup> mouse neutrophils. (D) *Grx1*<sup>-/-</sup> mouse neutrophils are unable to release DNA. Confocal microscopy. DNA release was analyzed after short-term stimulation (total 35 min) of WT and *Grx1*<sup>-/-</sup> mouse neutrophils with the indicated triggers. Right: Quantification of released dsDNA in supernatants of activated neutrophils. (E) Disruption of MT network formation does not affect actin polymerization. Confocal microscopy. F-actin distribution and morphological changes were analyzed after pretreatment and short-term stimulation (total 35 min) of human neutrophils with the indicated inhibitors and triggers. Right: Quantification of F-actin was performed by automated analysis of microscopic images by using Imaris software. Data are means ± SEM. \*\*\*, P < 0.001. n = 5. Bars, 10 μm.



Video 1. Time-lapse confocal microscopy. Cytoplasmic actin and tubulin rearrangements were observed on mouse neutrophil activation over a period of 47 min. Please see also Fig. S1 A. *Lifeact*-EGFP mouse neutrophils were primed briefly with GM-CSF and activated with C5a. Neutrophils expressed EGFP-labeled actin and were further stained for 30 min with SiR-tubulin to visualize the tubulin. Nuclear DNA was stained with Hoechst 33342. At the earlier time points, cortical F-actin was seen in a ring-like manner close to the cell membrane. GM-CSF-primed and C5a-activated neutrophils demonstrated F-actin accumulation at the leading edge of the cells and increasing MT network formation. Bar, 10 μm.